Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

SOPHiA GENETICS (SOPH) EBIAT (2020 - 2025)

SOPHiA GENETICS's EBIAT history spans 6 years, with the latest figure at -$19.2 million for Q4 2025.

  • On a quarterly basis, EBIAT fell 26.53% to -$19.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$79.0 million, a 26.41% decrease, with the full-year FY2025 number at -$79.0 million, down 26.41% from a year prior.
  • EBIAT hit -$19.2 million in Q4 2025 for SOPHiA GENETICS, up from -$20.0 million in the prior quarter.
  • Over the last five years, EBIAT for SOPH hit a ceiling of -$12.7 million in Q1 2021 and a floor of -$25.5 million in Q1 2022.
  • Historically, EBIAT has averaged -$19.1 million across 5 years, with a median of -$19.4 million in 2023.
  • The widest YoY moves for EBIAT: up 99.8% in 2021, down 103.93% in 2021.
  • Tracing SOPH's EBIAT over 5 years: stood at -$21.4 million in 2021, then surged by 34.64% to -$14.0 million in 2022, then tumbled by 72.21% to -$24.1 million in 2023, then surged by 37.0% to -$15.2 million in 2024, then dropped by 26.53% to -$19.2 million in 2025.
  • Business Quant data shows EBIAT for SOPH at -$19.2 million in Q4 2025, -$20.0 million in Q3 2025, and -$22.4 million in Q2 2025.